



EUROPEAN MEDICINES AGENCY  
SCIENCE MEDICINES HEALTH

**Public Declaration of Interests and Confidentiality Undertaking of  
European Medicines Agency (EMA),  
Scientific Committee members and experts**

**Public declaration of interests**

**I, Susanna Palkonen**

**Organisation/Company:** European Patients Forum (EPF)

**Country:** Belgium

do hereby declare on my honour that, to the best of my knowledge, the only direct or indirect interests I have in the pharmaceutical industry are those listed below:

2.1 Employment

No interest declared

2.2 Consultancy

No interest declared

2.3 Strategic advisory role

| Period            | Company         | Products  | Therapeutic Indication |
|-------------------|-----------------|---|------------------------|
| 01/2008-(current) | GlaxoSmithKline | GSK European Health Advisory Board: patient centredness of the company, including: EU health policy, transparency, ethics     |                        |
| 07/2014-07/2014   | Novartis        | Participation in Novartis meeting for patient groups around the globe to discuss further patient involvement in company's R&D |                        |

2.4 Financial interests

No interest declared

2.5 Principal investigator

No interest declared

2

## 2.6 Investigator

No Interest Declared

## 2.7 Grant / Funding to organisation /institution

| Company  | Subject Matter   |
|--|--|
| GSK  | EPF: ?60.000 unrestricted grant Operating Programme and Capacity Building Programme        |
| Hoffman La Roche   | EPF: ?15.000 unrestricted grant  |
| Janssen  | EPF: ?30.000 unrestricted grant on Capacity Building programme                             |
| Shire  | EPF: ?10.000 unrestricted grant  |
| Amgen  | EPF: ?35.000 unrestricted grant Capacity Building Programme                                |
| CSL Behring  | EPF: ?10.000 Project Portfolio   |
| Pfizer   | EPF: ?42.900 unrestricted grant Operating Programme and Capacity Building Programme        |
| Almirall   | EPF: ?5.000 unrestricted grant Operating Programme   |
| Baxter   | EPF: ?10.000 unrestricted grant Capacity Building Programme                                |
| Sanofi Pasteur   | EPF: ?10.000 unrestricted grant Operating Programme  |
| EUPATI project (IMI-JU) industry consortium (UCB, Amgen, Genzyme, VFA, AZ, Novonordisk, Bayer, Merck, Janssen, GSK, Chiesi, Hoffmann, Lilly, Novartis, Esteve) | EPF: ? 62.709,74 EUPATI project co-funding   |
| Gilead   | EPF: ? 20.000 unrestricted grant Operating Programme                                       |
| Johnson & Johnson  | EPF: ? 10.000 unrestricted grant   |
| Eli-Lilly  | EPF: ? 15.000 Capacity Building Programme  |
| MSD  | EPF: ? 58.891.61 unrestricted grant Operating Programme and Empowerment Campaign           |
| Alexion  | EPF: ? 10.000 unrestricted grant Capacity Building Programme                               |
| Mylan  | EPF: ? 10.000 unrestricted grant Project Portfolio   |
| Servier  | EPF: ? 10.000 Project Portfolio  |
| TEVA   | EPF: ? 20.000 unrestricted grant on Project Development                                    |
| Celgene  | EPF: ?15.000 unrestricted grant Capacity Building Programme                                |
| Novartis   | EPF: ?60.000 unrestricted grant Operating Programme and Capacity Building Programme        |
| Vertex   | EPF: ?15.000 unrestricted grant Capacity Building Programme                                |
| AIPP   | EPF: ?20.000 unrestricted grant Capacity Building Programme                                |
| Bosch Foundation   | EPF: ?20.000 unrestricted grant Empowerment Campaign                                       |
| AirLiquide Healthcre   | EFA: unrestricted grant ?30.000 Operating programme  |
| ALK Abello   | EFA: unrestricted grant ?30.000 Operating programme and 8.000 Interest Group Project       |
| Astra Zeneca   | EFA: unrestricted grant ?30.000 Operating programme and ? 30.000 Asthma Project            |
| Boehringer Ingelheim   | EFA: unrestricted grant ?30.000 Operating programme and ? 28.000 Capacity Building Project |
| Chiesi   | EFA: unrestricted donation ?5.000 Operating programme                                      |
| GSK  | EFA: unrestricted grant ?30.000 Operating programme and ? 30.000 Asthma Project            |

|                  |  |
|------------------|--|
| Novartis         | EFA: unrestricted grant ?30.000 Operating programme and ? 30.000 Asthma Project, ?8.000 Interest Group, ?30.000 CRD Campaign |
| TEVA             | EFA: unrestricted grant ?30.000 Operating programme and ? 30.000 Asthma Project  |
| Stallergenes     | EFA: unrestricted grant ?30.000 Operating programme  |
| Roche            | EFA: unrestricted grant ?30.000 Operating programme  |
| Sig Air Handling | EFA: unrestricted grant ?15.000 Operating programme  |
| LigeGas          | EFA: unrestricted donation ?4.500 Operating programme  |
| Sanofi           | EFA: unrestricted grant ?30.000 Operating programme  |

## 2.8 Close family member interest

No interest declared

## 2.9 Any other interests or facts

The information to funding above is based on the 2016 actual funding for the organisations I am affiliated with. I am employed by the European Federation of Allergy and Airways Diseases Patients' Associations (EFA) as Director and a volunteer member of the board (vice president) of the EPF, therefore I am declaring the funding of both organisations.

The funding arrangements, code of conduct, disclosure and annual reports of the EPF, of which I am the Vice President are available at <http://www.eupatient.eu/About-EPF/Transparency/>

The funding arrangements, code of conduct, disclosure and annual reports of the EFA are available at <http://www.efanet.org/who-we-are/funding-partners>

I also participate on an hoq basis to the EFPIA THINK-TANK for patient groups and the EPF-EUCOMED MedTech Dialogue meetings, and EFA works closely with the scientific societies European Academy of Allergology and Clinical Immunology (EAACI) and European Respiratory Society (ERS), including the ERS foundation, European Lung Foundation, who receive funding from the pharmaceutical industry and and I am a member of the Ethics Board of the eTriks <http://www.etriks.org/> project and EFA is a partner of the U-BIOPRED from the IMI and the FP7 EARIP projects where industry are partners.

## CONFIDENTIALITY UNDERTAKING

In view of the following definitions:

**"EMA Activities"** encompass any meeting (including meeting preparation and follow-up, associated discussion or any other related activity) of the European Medicines Agency's Management Board, Committees, Working Parties, Expert Groups, or any other such meeting; work as an expert on assessments; work as an expert on guidance development.

**"Confidential Information"** means all information, facts, data and any other matters of which I acquire knowledge, either directly or indirectly, as a result of my EMA Activities.

**"Confidential Documents"** mean all drafts, preparatory information, documents and any other material, together with any information contained therein, to which I have access, either directly or indirectly, as a result of my participation in EMA Activities. Furthermore, any records or notes made by me relating to Confidential Information or Confidential Documents shall be treated as Confidential Documents.

I understand that I may be invited to participate either directly or indirectly in certain EMA activities and hereby undertake:

- To treat all Confidential Information and Confidential Documents under conditions of strict confidentiality.
- Not to disclose (or authorise any other person to disclose) in any way to any third party any Confidential Information or Confidential Document.
- Not to use (or authorise any other person to use) any Confidential Information or Confidential Document other than for the purposes of my work in connection with EMA activities.

- To dispose of Confidential Documents as confidential material as soon as I have no further use for them.

This undertaking shall not be limited in time, but shall not apply to any document or information that I can reasonably prove was known to me before the date of this undertaking or which becomes public knowledge other than as a result of a breach of any of the above undertakings.

I confirm the information declared on this form is accurate to the best of my knowledge and I acknowledge that my information will be stored electronically and published on the EMA website.

|                   |                  |
|-------------------|------------------|
| <b>Full Name:</b> | Susanna Palkonen |
| <b>Date:</b>      | 2017-03-13       |

*For Definitions of activities etc, refer to Policy on Handling of Conflicts of Interest / Electronic DOI template*